STAMP2 Attenuates Cardiac Dysfunction and Insulin Resistance in Diabetic Cardiomyopathy via NMRAL1-Mediated NF-κB Inhibition in Type 2 Diabetic Rats
Zhan Gao,Yun Ti,Bin Lu,Fang-qiang Song,Lei Zhang,Bo-ang Hu,Jia-ying Xie,Wei Zhang,Lu Han,Ming Zhong
DOI: https://doi.org/10.2147/DMSO.S374784
2022-10-20
Abstract:Zhan Gao, 1, 2 Yun Ti, 1 Bin Lu, 1 Fang-qiang Song, 1, 3 Lei Zhang, 1 Bo-ang Hu, 1 Jia-ying Xie, 1 Wei Zhang, 1 Lu Han, 1, 4 Ming Zhong 1 1 The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese National Health Commission and Chinese Academy of Medical Sciences, The State and Shandong Province Joint Key Laboratory of Translational Cardiovascular Medicine, Department of Cardiology, Qilu Hospital, Qilu College of Medicine, Shandong University, Jinan, People's Republic of China; 2 Department of Cardiology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, People's Republic of China; 3 Department of Critical Care Medicine, Tengzhou Central People's Hospital, Tengzhou, People's Republic of China; 4 Department of General Practice, Qilu Hospital, Qilu College of Medicine, Shandong University, Jinan, People's Republic of China Correspondence: Lu Han; Ming Zhong, Email ; Background: Previous studies have reported that six transmembrane protein of prostate 2 (STAMP2) attenuates metabolic inflammation and insulin resistance in diabetes mellitus. However, the role of STAMP2 in the diabetic heart is still unclear. Methods: A diabetic rat cardiomyopathy model was established via intraperitoneal STZ injection. STAMP2 was overexpressed in the treatment group using adeno-associated virus. Rat heart diastolic function was measured using echocardiography and a left ventricular catheter, and cardiac interstitial fibrosis was detected by immunohistochemistry and histological staining. Insulin sensitivity and NF-κB expression were shown by Western blotting. NMRAL1 distribution was illustrated by immunofluorescence. Results: STAMP2 expression in the diabetic rat heart was reduced, and exogenous overexpression of STAMP2 improved glucose tolerance and insulin sensitivity and alleviated diastolic dysfunction and myocardial fibrosis. Furthermore, we found that NF-κB signaling is activated in the diabetic heart and that exogenous overexpression of STAMP2 promotes NMRAL1 translocation from the cytoplasm to the nucleus and inhibits p65 phosphorylation. Conclusion: STAMP2 attenuates cardiac dysfunction and insulin resistance in diabetic cardiomyopathy, likely by promoting NMRAL1 retranslocation and NF-κB signaling inhibition. Keywords: STAMP2, diabetic cardiomyopathy, NADPH, NMRAL1, NF-κB Diabetes mellitus has caused tremendous health and economic burdens worldwide. Among them, heart failure and other cardiovascular complications have been demonstrated to be the most common cause of death. Diabetic cardiomyopathy (DCM) greatly increases the incidence and mortality of heart failure. 1 DCM is characterized by overt myocardial interstitial fibrosis and decreased diastolic function. Numerous theories have been proposed to explain the mechanism of severe interstitial fibrosis. Insulin resistance is indicated by abundant research to trigger DCM occurrence and development. 2 However, the mechanism underlying insulin resistance and leading to altered myocardial structure remains incompletely understood. STAMP2 (six-transmembrane protein of prostate 2), also known as STEAP4 (six-transmembrane epithelial antigen of prostate 4), belongs to a family of six-transmembrane proteins. Three of the four family members, including STAMP2, have been characterized as reductases because they all have NADPH oxidoreductase motifs. 3 Recent studies have found that STAMP2 significantly improves insulin resistance in a variety of cells and animal models. For example, STAMP2 knockout mice exhibit overt inflammation, spontaneous insulin resistance, glucose intolerance, mild hyperglycemia, dyslipidemia, and fatty liver disease, 4 while overexpressing STAMP2 in diabetic mice reduced proinflammatory cytokine levels and improved insulin resistance by inhibiting JNK phosphorylation. 5 Accelerated hepatic steatosis and insulin resistance were observed in STAMP2 knockout mice; conversely, adenoviral STAMP2 improved hepatocyte lipid accumulation, hepatic steatosis and insulin resistance via sterol response element binding protein 1 (SREBP1) and the PPARγ pathway. 6 To date, two questions remain unanswered. First, how is STAMP2 capable of alleviating metabolic disorders, inflammatory signaling and insulin resistance? Additionally, although DCM is a typical metabolic disease and the heart is an organ with high STAMP2 expression, 7 there has not been any research concerning STAMP2 in DCM. We assume that the biological function of STAMP2 is mediated by its NADPH oxidoreductase motif. -Abstract Truncated-
endocrinology & metabolism